Moul JW. - Prostate specific antigen only progression of prostate cancer. J Urol, 2000, 163, 1632-1642. (Pubitemid 30366704)
Fagundo EV, Amo FH, López EL, et al. - Risk factors for biochemical recurrence after radical prostatectomy in patients with clinically localized prostate cancer. Implications of adjuvant treatment. Arch Esp Urol, 2012, 65, 158-165.
Frazier HA, Robertson JE, Humphrey PA, et al. - Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol, 1993, 149, 516-518. (Pubitemid 23094042)
Trapasso JG, deKernion JB, Smith RB, et al. - The incidence and the significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol, 1994, 152, 1821-1825. (Pubitemid 24322638)
Wiegel T, Bottke D, Steiner U, et al. - Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol, 2009, 27, 2924-2930.
Thompson IM, Tangen CM, Paradelo J, et al. - Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow up of a randomized clinical trial. J Urol, 2009, 181, 956-962.
Bolla M, Van Poppel H, Collette L, et al. - Preliminary results for EORTC trial 22911: radical prostatectomy followed by postoperative radiotherapy in prostate cancers with a high risk of progression. Cancer Radiother, 2007, 11, 363-369. (Pubitemid 350110551)
Daly T, Hickey BE, Lehman M, et al. - Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database Syst Rev, 2011, 12, CD007234.
ESMO Guidelines Task Force. - ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann Oncol, 2005, 16 (Suppl 1), 134-136.
Cher ML, Bianco FJ, Lam SJ, et al. - Limited role of radionucleide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy: when is it indicated? BJU Int, 2004, 94, 299-302.
Choueiri TK, Dreicer R, Paciorek A, et al. - A model that predics the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol, 2008, 179, 906-910.
Freedland SJ, Humphrey EB, Mangold LA. - Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA, 2005, 294, 433-439. (Pubitemid 41124175)
Pound CR, Partin AW, Eisenberger MA, et al. - Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 1999, 281, 1591-1597. (Pubitemid 29211767)
Pollack A, Zagars GK, Kavadi VS. - Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer, 1994, 74, 670-678. (Pubitemid 24217632)
Lee WR, Hanks GE, Hanlon A. - Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol, 1997, 15, 230-238. (Pubitemid 27020578)
